CAJ | 학술논문

目的：观察七叶皂苷钠辅助治疗胫骨平台骨折的临床研究效果。方法胫骨平台骨折患者160例，根据随机抽签原则分为观察组与对照组，每组各80例，都采用改良双侧钢板内固定治疗与常规干预，观察组在此基础上于术后加用七叶皂苷钠静脉滴注。结果2组的手术时间、术中出血量与临床骨折愈合时间对比差异都无统计学意义。观察组干预后的关节炎、下肢深静脉血栓、关节僵硬和关节不稳定等并发症总发生率显著低于对照组（P<0.05），观察组干预后的关节活动度与HSS值都显著高于对照组，对比差异有统计学意义（P<0.05）。2组干预前的血浆TNF-α含量对比差异无统计学意义，干预后上述值都明显下降，与干预前对比差异显著（P<0.05），同时组间对比差异显著（P<0.05）。结论七叶皂苷钠辅助治疗胫骨平台骨折有很好的预后效果，其作用机理可能与降低血浆TNF-α水平有关。
목적：관찰칠협조감납보조치료경골평태골절적림상연구효과。방법경골평태골절환자160례，근거수궤추첨원칙분위관찰조여대조조，매조각80례，도채용개량쌍측강판내고정치료여상규간예，관찰조재차기출상우술후가용칠협조감납정맥적주。결과2조적수술시간、술중출혈량여림상골절유합시간대비차이도무통계학의의。관찰조간예후적관절염、하지심정맥혈전、관절강경화관절불은정등병발증총발생솔현저저우대조조（P<0.05），관찰조간예후적관절활동도여HSS치도현저고우대조조，대비차이유통계학의의（P<0.05）。2조간예전적혈장TNF-α함량대비차이무통계학의의，간예후상술치도명현하강，여간예전대비차이현저（P<0.05），동시조간대비차이현저（P<0.05）。결론칠협조감납보조치료경골평태골절유흔호적예후효과，기작용궤리가능여강저혈장TNF-α수평유관。
Objective To investigate the clinical effects of sodium aescinate adjuvant in treatment with tibial plateau fracture. Method According to the principle of random draw, 160 cases of tibial plateau fractures patients were divided into observation group and control group, each had 80 cases. All cases were given the improved bilateral plate internal ifxation with conventional interventions, besides, the observation group were added intravenous infusion of sodium aescinate after surgery. Results The differences of operative time, blood loss and clinical fracture healing time between two groups were not signiifcant. After intervention, the overall incidence of complications with arthritis, deep vein thrombosis, joint stiffness and joint instability in observation group were signiifcantly lower than that in control group, but the value of joint activity with the HSS values were signiifcantly higher(P<0.05). The plasma TNF-αlevels between two groups before the intervention was not signiifcant, and the values were signiifcantly decreased after the intervention (P<0.05), and had signiifcant differences between the two groups (P<0.05). Conclusion Sodium aescinate has good effect on prognosis in treatment with tibial plateau fractures, the mechanism may be related to reducing the level of plasma TNF-α.